Oscar Health enters its third-quarter report with a problem most insurers would envy: it may have already earned more than its full-year profit target. The company produced roughly $1.09 billion in earnings from operations across the first two quarters, yet its raised 2026 outlook calls for only $500 million to $700 million for the year. That gap implies a meaningful operating loss in the back half. That pattern is typical for individual market plans as members burn through deductibles, but it puts the burden of proof on this report. The question is whether the third quarter looks like normal seasonal giveback or the start of something less comfortable.
Wall Street expects a loss of $0.11 per share on revenue of $4.72 billion. That compares with a loss of $0.53 a year ago on $2.99 billion in revenue, so the quarter still reflects roughly 58% top-line growth and a sharply narrower loss. The Earnings Whisper of $0.01 sits modestly above consensus, suggesting the informal bar is roughly breakeven rather than a loss. On revenue, management has held its $18.7 billion to $19.0 billion range for three straight quarters, and the $18.92 billion consensus sits in the upper half. That leaves little cushion if membership erodes faster than planned.
Membership is the first thing to scrutinize. Last quarter management warned that back-half churn would run at about twice the earlier 1% to 2% monthly pace. The cause is delayed CMS program-integrity disenrollments, drawn from an industry list of roughly 1 million members concentrated in Florida and Texas. Management described this as a timing issue with no revenue impact, and the modest sequential step down from $4.88 billion in second-quarter revenue is consistent with that view. A revenue figure that lands near consensus, alongside a full-year range that is reaffirmed again, would validate the timing argument. A shortfall or a trimmed range would suggest the disenrollments are cutting deeper than expected.
The medical loss ratio is the second test. The guidance raise rested on a better MLR outlook of 81.5% to 82.5%, record-low SG&A of 14.2% in the second quarter, and an early claims-based morbidity read that management called quite favorable to pricing. Management said that morbidity upside was not yet in guidance, which is the most interesting potential source of a further raise. Against that, outpatient utilization ran elevated through the first half, a new concern compared with the quiet utilization picture described in the first quarter. If outpatient trends stabilized and later risk-adjustment data held up, the MLR target looks conservative. If not, the cushion is thinner than it appears. That matters because about $232 million of year-to-date favorable prior-period development, including a $160 million 2025 risk-adjustment true-up, nearly matched the $250 million raise. Core underwriting, not one-time items, needs to carry the next leg.
The market has been generous since the last report. Shares have gained 13.9% while the S&P 500 was flat, and at $31.35 the stock trades well above its 200-day moving average of $23.37. It sits about 10% below its post-earnings high of $35.01, so this is a recovering stock rather than one pressing a breakout. Sentiment, however, has slipped from mildly bullish before the prior report to mildly bearish now, a sign that some investors worry the easy gains are behind the company. Progress on newer initiatives, including the ICRAx data exchange, Lucy retail partners such as Allstate and Aflac, and AI-driven pharmacy savings, would help, but these remain secondary to the core numbers.
Ultimately, the report hinges on whether Oscar can show that its 2026 profitability reflects durable pricing and cost discipline rather than favorable reserve releases. A third-quarter loss in line with seasonal expectations, a steady MLR, and a reaffirmed or raised operating outlook would keep the turnaround narrative intact. Signs of rising utilization or deeper membership losses would invite the market to question how much of the year's success can be repeated in 2027.